# India Thyroid Disorder Market

> India Thyroid Disorder Market Research Report: Size, Share, Trend Analysis By Types (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy, Surgery), By Route of Administration (Oral, Intravenous, others) and By End Users (Hospitals, Clinics, others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.67%
- **2024:** $ 125.56 Million
- **2025:** $ 130.17 Million
- **2035:** $ 186.6 Million
- **Key Players:** AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), AstraZeneca (GB)

**Report ID:** MRFR/MED/55243-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-thyroid-disorder-market-57009

---

## Market Summary

## **India Thyroid Disorder Market Overview**

As per MRFR analysis, the India Thyroid Disorder Market Size was estimated at 96.4 (USD Million) in 2024.The India Thyroid Disorder Market Industry is expected to grow from 101.2(USD Million) in 2025 to 214.56 (USD Million) by 2035. The India Thyroid Disorder Market CAGR (growth rate) is expected to be around 7.071% during the forecast period (2025 - 2035).

## **Key India Thyroid Disorder Market Trends Highlighted**

The India Thyroid Disorder Market is experiencing significant growth driven by increasing awareness of thyroid diseases and the rising prevalence of related health issues. As lifestyles change, more people are adopting sedentary habits, which contribute to the rise in thyroid disorders. Government awareness campaigns and initiatives to promote health screenings have played a crucial role in educating the population about the importance of thyroid health, thereby boosting demand for diagnosis and treatment options. Additionally, the growing adoption of diagnostic tests, including blood tests for hormone levels, is providing patients and healthcare providers with better tools for early detection and management.

Opportunities in the market are also expanding as there is a rising focus on personalized medicine tailored to individual patient needs. New advancements in technology and research are paving the way for innovative treatment options, including biologics and gene therapies. The integration of telemedicine in healthcare is facilitating better access to specialists for remote consultations, especially in rural areas of India where healthcare facilities may be limited. Recent trends indicate that there is also a shift towards holistic treatment approaches, combining conventional medicine with lifestyle modifications and alternative therapies. 

This trend reflects growing consumer interest in overall well-being as they seek comprehensive solutions to manage thyroid conditions.Research is increasingly highlighting the impact of diet and nutrition on thyroid health, resulting in a demand for supplements and dietary changes among patients. The combination of these drivers and trends suggests a dynamic landscape for the thyroid disorder market in India, with ample potential for growth and innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **India Thyroid Disorder Market Drivers**

Increasing Prevalence of Thyroid Disorders in India

The growing incidence of thyroid disorders in India is a significant driver for the India Thyroid Disorder Market Industry. Studies indicate that approximately 42 million people in India are affected by thyroid disorders, particularly hypothyroidism and hyperthyroidism. This rising prevalence can be attributed to various factors including lifestyle changes, dietary deficiencies, and increased stress levels among the Indian population.

The Indian Council of Medical Research highlights that the cases of thyroid disorders are expected to rise further due to urbanization and changes in dietary habits, which is likely to spur the demand for diagnostic tests and treatment options in the India Thyroid Disorder Market Industry.

Additionally, with an increase in awareness regarding thyroid health, more individuals are seeking medical consultations, thereby positively affecting market growth. Enhanced screening initiatives have been promoted by government and health organizations, leading to earlier and more comprehensive diagnosis, which is imperative in addressing thyroid disorders effectively. As a result, the cumulative effect of these factors will potentially contribute to the growth trajectory of the India Thyroid Disorder Market Industry.

Growth in Healthcare Infrastructure and Diagnostic Facilities

The expansion of healthcare infrastructure and enhanced diagnostic facilities in India is a crucial factor driving the India Thyroid Disorder Market Industry. The Government of India has been actively investing in healthcare systems through initiatives like the National Health Mission, which aims to improve healthcare access and quality across the country. The establishment of new diagnostic centers and advancements in medical technology have led to an increase in the availability of accurate diagnostic tests for thyroid disorders.

As stated by the Ministry of Health and Family Welfare, healthcare expenditure in India will increase, subsequently giving rise to advanced diagnostic solutions. Better access to reliable tests will motivate people to get screened, which will subsequently boost the overall market for thyroid disorder diagnostics and treatments in the India Thyroid Disorder Market Industry.

Rising Awareness and Education about Thyroid Health

The increasing awareness of thyroid health among the Indian population is significantly driving the India Thyroid Disorder Market Industry. Various campaigns and initiatives launched by health organizations to educate the public about thyroid disorders have played a crucial role in this growth. The Thyroid Federation of India and other health NGOs are conducting workshops and seminars to raise awareness about symptoms, risk factors, and the importance of early detection.

Reports suggest that around 60% of people suffering from thyroid issues are unaware of their condition, indicating a large untapped market. The promotion of educational programs has led to more individuals seeking medical advice and timely diagnosis of thyroid disorders, which directly supports revenue growth in the India Thyroid Disorder Market Industry.

## **India Thyroid Disorder Market Segment Insights**

### **Thyroid Disorder Market Type Insights**

The India [Thyroid Disorder](../../../reports/thyroid-disorder-market-2747) Market demonstrates a diverse landscape shaped by various types of thyroid disorders, primarily focusing on Hypothyroidism and Hyperthyroidism. In India, Hypothyroidism is particularly prevalent, with a significant portion of the population suffering from this condition due to factors such as iodine deficiency, which has been a notable issue in various regions. This disorder is characterized by an underactive thyroid, leading to various health complications and the potential for increased healthcare costs, making its management a priority for patients and healthcare providers alike.

On the other hand, Hyperthyroidism, marked by an overactive thyroid gland, also presents significant challenges in the healthcare system. This condition can lead to a range of symptoms, including rapid heart rate, anxiety, and significant weight loss, requiring patients to seek immediate medical intervention. The increasing awareness and the rising incidence of thyroid disorders due to lifestyle changes and environmental factors are propelling the demand for effective diagnostic and therapeutic options in the country.

The India Thyroid Disorder Market segmentation reflects the critical need for targeted treatment approaches for both Hypothyroidism and Hyperthyroidism, which involve patient education and routine monitoring to ensure better health outcomes. Furthermore, the rising awareness of thyroid health is facilitating the growth of screening programs across India, thus contributing to the overall improvement in diagnosis rates. Increasing investment in Research and Development by pharmaceutical companies to develop advanced therapies and patient-centric treatment options further supports this market’s evolution.

Ultimately, as healthcare initiatives grow and more patients gain access to information on thyroid health, the focus on these types will intensify, ensuring better management of thyroid disorders and a larger impact on public health. The collective emphasis on both Hypothyroidism and Hyperthyroidism reflects their significant roles within the India Thyroid Disorder Market, with a sustained commitment to enhancing patient care and quality of life through medical advancements and effective healthcare policies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Thyroid Disorder Market Treatment Insights**

The Treatment segment of the India Thyroid Disorder Market plays a vital role in addressing the growing prevalence of thyroid conditions across the country. With an increasing awareness of thyroid health, the market has witnessed a systematic rise in demand for therapies that ensure effective management and care. Medications, primarily focused on hormone replacement and antithyroid drugs, are pivotal in regulating thyroid function and cater to a wider patient demographic. Radioactive Iodine Therapy is emerging as a significant option for hyperthyroidism treatment and thyroid cancer, providing a non-invasive approach that often leads to improved patient outcomes.

Meanwhile, Surgery remains a critical intervention for patients with large goiters or malignancies, where it provides definitive solutions that often lead to swift recovery. The diverse nature of treatment options across these areas reflects the necessity for tailored treatment approaches, aiding healthcare providers in delivering optimal care. The robust growth drivers for this segment include an aging population, urbanization, and increased healthcare access which reinforces the demand for effective treatment in the India Thyroid Disorder Market.

### **Thyroid Disorder Market Route of Administration Insights**

The Route of Administration segment is a crucial component of the India Thyroid Disorder Market, impacting how treatments are delivered to patients across the country. A significant portion of the market is attributed to oral administration, which is often preferred due to its convenience, ease of use, and patient compliance. This method allows patients to manage their thyroid conditions at home without the need for clinical supervision, thus enhancing adherence to treatment regimens. Intravenous administration, although less common, plays a vital role in severe cases where rapid drug action is required, often in clinical settings.

This method can provide immediate effects, making it particularly important for patients undergoing acute care. Other methods of administration also contribute to the market, catering to specific patient needs and preferences. The growing awareness about thyroid-related disorders and the increasing prevalence of these conditions in India drive the demand within this segment. 

In addition, advancements in drug formulation and delivery methods present significant opportunities for innovation and market growth in the Indian healthcare landscape. The importance of the Route of Administration segment underscores its role in ensuring effective management of thyroid disorders, aligning with national health priorities to improve patient outcomes.

### **Thyroid Disorder Market End User Insights**

The India Thyroid Disorder Market has been witnessing significant growth, particularly in the End User segment where facilities such as hospitals and clinics play crucial roles in diagnosis and treatment. Hospitals are essential as they provide advanced medical technologies and comprehensive care for thyroid disorders, accommodating a large patient base. Clinics, on the other hand, offer accessible and cost-effective treatment options, ensuring early detection and management of thyroid-related issues. The increasing incidence of thyroid disorders in India, partially due to lifestyle changes and dietary habits, has led to heightened demand for these healthcare settings.

As more individuals seek thyroid testing and treatment, the importance of these End Users grows, with hospitals and clinics becoming pivotal in addressing health concerns. Furthermore, governmental initiatives aimed at enhancing healthcare infrastructure and services contribute to the development and expansion of the End User segment, facilitating better patient access to thyroid disorder management. Overall, the combination of increasing awareness, improved accessibility, and evolving healthcare policies drives the significant role of these End Users within the India Thyroid Disorder Market.

**India Thyroid Disorder Market Key Players and Competitive Insights****:**

The India Thyroid Disorder Market is characterized by a growing awareness of thyroid health, leading to increased diagnosis and treatment of disorders such as hypothyroidism and hyperthyroidism. The market is influenced by various factors, including a rise in the prevalence of thyroid-related diseases, advancements in medical technology, ongoing research activities in endocrinology, and government initiatives to improve healthcare accessibility. 

Competition in this market is driven by a mix of multinational corporations and domestic pharmaceutical companies, each striving to innovate and expand their product offerings. The competitive landscape is marked by a focus on quality, affordability, and availability of medications, leading to a diverse range of products aimed at addressing the specific needs of patients suffering from thyroid disorders.

Lupin operates with a solid presence in the India Thyroid Disorder Market, manifesting strengths such as a robust research and development pipeline and a wide range of high-quality generic medications. The company has established itself as a key player by offering effective thyroid medication that aligns with the needs of the Indian population. With a commitment to affordability, Lupin has made its products accessible to a diverse customer base, contributing to an increased market share. The firm emphasizes partnerships with healthcare professionals to better understand patient requirements, which has resulted in a trusted reputation within the medical community. 

Additionally, Lupin's strategic marketing approaches help enhance brand recall, further solidifying its position in this therapeutic area.BristolMyers Squibb holds a vital role in the India Thyroid Disorder Market, bringing a legacy of innovation and commitment to patient care. The company offers a selection of thyroid medications designed to cater to the varying needs of patients, ensuring efficacy and safety. BristolMyers Squibb benefits from a well-structured distribution network in India, allowing for widespread accessibility to its products across urban and rural settings. 

The company’s strengths lie in its focus on clinical research and continuous development, which enables it to stay ahead of industry changes and emerging patient needs. Strategic mergers and acquisitions in related healthcare sectors have allowed BristolMyers Squibb to enhance its market presence and leverage synergies, creating a competitive advantage while upholding the highest standards of quality. This stronghold in the market, coupled with a keen understanding of local healthcare dynamics, positions BristolMyers Squibb effectively within the thyroid disorder landscape in India.

**Key Companies in the India Thyroid Disorder Market Include:**

- Lupin
- BristolMyers Squibb
- GSK
- Bayer
- Dr. Reddy's Laboratories
- Sun Pharmaceutical
- Eli Lilly
- Abbott
- Roche
- Merck
- Sanofi
- Mylan
- AstraZeneca
- Novartis
- Pfizer

**India Thyroid Disorder Market Industry Developments**

In recent months, the India Thyroid Disorder Market has seen significant developments, including increased awareness and diagnosis rates among the population. Noteworthy is the growth of companies like Lupin, Sun Pharmaceutical, and Dr. Reddy's Laboratories, which have strengthened their portfolios in thyroid medications through Research and Development initiatives and strategic marketing campaigns. In July 2023, Sun Pharmaceutical expanded its distribution channels for its thyroid formulations, effectively reaching a larger patient base. 

Additionally, the market has been influenced by an upturn in health awareness programs orchestrated by governmental health agencies, leading to an uptick in diagnosed cases of hypothyroidism and hyperthyroidism. In terms of mergers and acquisitions, there have been no notable announcements relating directly to major companies such as Pfizer, Merck, or GSK specifically within the thyroid segment in India. However, the overall valuation of the market is projected to grow, driven by the aging population and increasing prevalence of thyroid disorders. Furthermore, the emergence of telehealth services has facilitated better access to endocrinologists, fostering patient engagement and adherence to treatments.

## **India Thyroid Disorder Market Segmentation Insights**

### **Thyroid Disorder Market Type****Outlook**

- Hypothyroidism
- Hyperthyroidism

### **Thyroid Disorder Market Treatment****Outlook**

- Medications
- Radioactive Iodine Therapy
- Surgery

### **Thyroid Disorder Market Route of Administration****Outlook**

- Oral
- Intravenous
- others

### **Thyroid Disorder Market End User****Outlook**

- Hospitals
- Clinics
- others

## Market Drivers

### Growing Geriatric Population

The increasing geriatric population in India is a significant factor influencing the thyroid disorder market. Older adults are more susceptible to thyroid disorders, particularly hypothyroidism and hyperthyroidism. As the demographic landscape shifts, with projections indicating that the elderly population will reach 300 million by 2050, the demand for thyroid-related healthcare services is expected to rise. This demographic trend may lead to a greater need for screening, diagnosis, and treatment options tailored to older patients. Consequently, the thyroid disorder market is likely to expand in response to the healthcare needs of this growing population segment.

### Rising Demand for Personalized Medicine

The trend towards personalized medicine is emerging as a key driver in the thyroid disorder market. Patients are increasingly seeking tailored treatment plans that consider their unique genetic and biochemical profiles. This shift is prompting pharmaceutical companies to invest in research and development of targeted therapies for thyroid disorders. The market is likely to see a rise in the availability of personalized treatment options, which may improve patient adherence and outcomes. Additionally, the integration of genetic testing into routine clinical practice could further enhance the precision of thyroid disorder management, thereby expanding the market's potential.

### Increasing Prevalence of Thyroid Disorders

The rising incidence of thyroid disorders in India is a crucial driver for the thyroid disorder market. Recent studies indicate that approximately 42 million individuals in India are affected by thyroid-related conditions, with hypothyroidism being the most prevalent. This growing patient population necessitates enhanced diagnostic and therapeutic solutions, thereby propelling market growth. the thyroid disorder market is expected to expand as healthcare providers focus on early detection and management of these conditions. Furthermore, the increasing awareness among the general public regarding thyroid health is expected to contribute to higher screening rates, which may lead to an uptick in demand for treatment options. As a result, the thyroid disorder market will experience significant growth in the coming years.

### Government Initiatives and Healthcare Policies

Government initiatives aimed at improving healthcare access and awareness are pivotal in shaping the thyroid disorder market. The Indian government has implemented various health programs to address non-communicable diseases, including thyroid disorders. These initiatives often include subsidized screening and treatment options, which can enhance patient access to necessary healthcare services. Additionally, public health campaigns focused on educating the population about thyroid health are likely to increase early diagnosis rates. As a result, the thyroid disorder market may experience a surge in demand for diagnostic tests and treatment modalities, driven by supportive healthcare policies and increased funding for thyroid health initiatives.

### Technological Advancements in Diagnostic Tools

advancements in diagnostic technologies significantly influence the thyroid disorder market. Innovations such as high-sensitivity thyroid function tests and imaging techniques have improved the accuracy and speed of diagnosis. These technological improvements facilitate early detection of thyroid disorders, which is essential for effective management. Moreover, the introduction of point-of-care testing devices allows for rapid assessment in various healthcare settings, potentially increasing patient compliance and follow-up. As diagnostic capabilities continue to evolve, the thyroid disorder market will benefit from enhanced testing options, leading to better patient outcomes and increased treatment uptake.

## Future Outlook

The [Thyroid Disorder Market](https://www.marketresearchfuture.com/reports/thyroid-disorder-market-2747) in India is projected to grow at a 3.67% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring.
- Investment in AI-driven diagnostic tools for early detection.
- Expansion of personalized medicine approaches tailored to individual patient profiles.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Hypothyroidism (Largest) vs. Hyperthyroidism (Fastest-Growing)

In the India thyroid disorder market, the prevalence of hypothyroidism remains significant, capturing the largest share of the segment. This condition is characterized by an underactive thyroid gland, leading to a range of health complications. Conversely, hyperthyroidism is also prevalent but is recognized as the fastest-growing segment due to increased awareness, early diagnosis, and improved treatment options that enhance patient outcomes.

The growth trends in this market are driven by various factors, including a growing aging population, lifestyle changes, and the rising incidence of autoimmune diseases. Healthcare providers are focusing on early detection and effective treatment strategies, which are likely to boost the market for both conditions. Advances in technology and increased access to healthcare services are expected to further propel the growth, particularly for hyperthyroidism treatments as they gain popularity among patients.

Hypothyroidism: Dominant vs. Hyperthyroidism: Emerging

Hypothyroidism is currently the dominant segment in the market, characterized by its widespread recognition and established treatment pathways. Patients commonly require lifelong management, which contributes to steady demand for thyroid hormone replacement therapies. On the other hand, hyperthyroidism is viewed as an emerging segment with a notably increasing diagnosis rate. Factors such as genetic predisposition and environmental triggers are pivotal in its rise. While treatment options for hyperthyroidism are expanding, including antithyroid medications and radioactive iodine, ongoing patient education and awareness campaigns are essential to enhance diagnosis and management. As healthcare systems evolve, both segments are poised for growth, with hypothyroidism maintaining its substantial market presence amidst the expanding hyperthyroid treatment landscape.

### By Treatment: Medications (Largest) vs. Radioactive Iodine Therapy (Fastest-Growing)

In the India thyroid disorder market, the treatment segment consists of three key values: Medications, Surgery, and Radioactive iodine therapy. Among these, Medications hold the largest share, making it the most preferred treatment option for patients dealing with thyroid disorders. Surgery and Radioactive iodine therapy, while important, take up comparatively smaller market shares. This distribution indicates a strong reliance on pharmaceutical interventions, which are often seen as less invasive and more manageable by patients.

Growth trends within the treatment segment reflect a rising demand for effective management of thyroid disorders with an increasing focus on Medications and Radioactive iodine therapy. The preference for Medications continues to dominate due to their accessibility and the ongoing development of new therapeutic drugs. Meanwhile, Radioactive iodine therapy is emerging as the fastest-growing option as advancements in treatment protocols and enhanced patient awareness drive its adoption, signaling an evolving landscape in treatment preferences among thyroid disorder patients.

Medications (Dominant) vs. Radioactive Iodine Therapy (Emerging)

Medications are the dominant force in the treatment segment due to their established efficacy and patient familiarity. They offer a range of options including hormone replacement therapies and antithyroid agents, catering to diverse patient needs. These treatments are typically more accessible and less invasive, making them the first line of defense against thyroid conditions. On the other hand, Radioactive iodine therapy is considered an emerging choice, particularly for hyperthyroidism and certain thyroid cancer patients. Its rapid growth can be attributed to increased recognition of its effectiveness and safety profile. As healthcare providers become more knowledgeable about this option, the adoption rates continue to rise, reflecting the shifting dynamics of treatment decisions in patients.

### By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the India thyroid disorder market, the route of administration is primarily dominated by the oral segment, which accounts for a significant market share. This can be attributed to the higher acceptance and convenience of oral medications among patients, making it the preferred choice for a majority of thyroid disorder treatments. In contrast, the intravenous route, while holding a smaller share, is rapidly gaining traction due to advancements in medical technology and an increase in the number of healthcare facilities enhancing patient care.

Growth trends within this segment indicate an increasing preference for the oral route, driven by factors such as patient convenience and ease of administration. However, the intravenous segment is quickly emerging as the fastest-growing, primarily fueled by the rising prevalence of severe thyroid disorders that require immediate therapeutic interventions. This trend is further supported by ongoing research and development aimed at improving intravenous formulations, making them more effective and appealing to healthcare providers.

Administration: Oral (Dominant) vs. Intravenous (Emerging)

The oral administration of medications is immensely popular in the India thyroid disorder market, positioning it as the dominant route due to its accessibility and patient compliance. Oral formulations, such as tablets and capsules, are widely accepted because they are easy to administer and carry less risk compared to injectable methods. On the other hand, intravenous administration is recognized as an emerging choice, particularly for patients facing severe thyroid conditions that necessitate immediate treatment. Although it represents a smaller portion of the market, intravenous administration is gaining attention due to advancements in delivery systems and the ability to offer rapid therapeutic effects, thereby enhancing treatment outcomes in critical scenarios.

### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the India thyroid disorder market, the distribution among end-user segments reveals that hospitals hold the largest share, primarily due to their capacity to provide comprehensive healthcare and specialized treatment for thyroid disorders. Meanwhile, clinics, while smaller in terms of overall market share, represent the fastest-growing segment, appealing to the increasing preference for outpatient care and personalized treatment plans.

The growth trends for these segments are largely driven by escalating awareness of thyroid disorders and the rising demand for early diagnosis and treatment options. Hospitals are expanding their services to accommodate a growing patient base, while clinics are capitalizing on the trend towards convenience and accessibility, establishing themselves as essential providers in managing thyroid health effectively.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals in the India thyroid disorder market play a dominant role by offering advanced treatment protocols and specialized care, benefiting from their extensive resources and multidisciplinary teams. They provide a full spectrum of diagnostic and therapeutic options to cater to a wide variety of thyroid disorders. On the other hand, clinics, emerging as a significant player, focus on streamlined, patient-centric approaches, often offering more affordable and accessible care. The convenience of local clinics is attracting more patients seeking timely diagnosis and treatment, which positions them as a crucial component of the healthcare landscape, complementing the services offered by hospitals.

## Competitive Benchmarking

The thyroid disorder market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as AbbVie (US), Merck & Co. (US), and Novartis (CH) are actively pursuing strategies that enhance their market presence and operational efficiency. AbbVie (US) focuses on developing novel therapies, which positions it favorably in a market that demands advanced treatment options. Meanwhile, Merck & Co. (US) emphasizes strategic collaborations with local healthcare providers to improve patient access to its products, thereby enhancing its competitive edge. Novartis (CH) is also investing in digital health initiatives, which reflects a broader trend towards integrating technology into healthcare solutions, thus shaping the competitive dynamics of the market.
The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to reduce costs and improve service delivery. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer (US) and Sanofi (FR) is significant, as they leverage their extensive distribution networks and brand recognition to maintain a competitive advantage.
In October 2025, Pfizer (US) announced a partnership with a leading Indian biotechnology firm to co-develop a new thyroid medication aimed at addressing unmet medical needs in the region. This collaboration is strategically important as it not only enhances Pfizer's product portfolio but also allows for localized development, which could lead to faster regulatory approvals and market entry. Such partnerships are indicative of a trend where multinational corporations seek to leverage local expertise to navigate the complexities of the Indian healthcare landscape.
In September 2025, Merck & Co. (US) launched a digital platform designed to facilitate patient engagement and education regarding thyroid disorders. This initiative is crucial as it aligns with the growing emphasis on patient-centric care, potentially improving treatment adherence and outcomes. By investing in digital solutions, Merck is likely positioning itself as a leader in the integration of technology within the healthcare sector, which could enhance its competitive standing.
In August 2025, Novartis (CH) expanded its manufacturing capabilities in India, focusing on the production of generic thyroid medications. This move is significant as it not only addresses the rising demand for affordable treatment options but also strengthens Novartis's supply chain resilience. By increasing local production, the company may reduce its dependency on imports, thereby mitigating risks associated with global supply chain disruptions.
As of November 2025, current trends in the thyroid disorder market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the dynamic healthcare landscape.

## Recent News & Developments

In recent months, the India Thyroid Disorder Market has seen significant developments, including increased awareness and diagnosis rates among the population. Noteworthy is the growth of companies like Lupin, Sun Pharmaceutical, and Dr. Reddy's Laboratories, which have strengthened their portfolios in thyroid medications through Research and Development initiatives and strategic marketing campaigns. In July 2023, Sun Pharmaceutical expanded its distribution channels for its thyroid formulations, effectively reaching a larger patient base. 

Additionally, the market has been influenced by an upturn in health awareness programs orchestrated by governmental health agencies, leading to an uptick in diagnosed cases of hypothyroidism and hyperthyroidism. In terms of mergers and acquisitions, there have been no notable announcements relating directly to major companies such as Pfizer, Merck, or GSK specifically within the thyroid segment in India. However, the overall valuation of the market is projected to grow, driven by the aging population and increasing prevalence of thyroid disorders. Furthermore, the emergence of telehealth services has facilitated better access to endocrinologists, fostering patient engagement and adherence to treatments.

## Report Scope

| MARKET SIZE 2024 | 125.56(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 130.17(USD Million) |
| MARKET SIZE 2035 | 186.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.67% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), AstraZeneca (GB) |
| Segments Covered | Type, Treatment, Route of Administration, End-User |
| Key Market Opportunities | Advancements in personalized medicine and digital health solutions enhance management of thyroid disorders. |
| Key Market Dynamics | Rising prevalence of thyroid disorders drives demand for innovative diagnostics and treatment solutions in the market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the overall market valuation of the thyroid disorder market in 2024?**
A: The overall market valuation was $125.56 Million in 2024.

**Q: What is the projected market valuation for the thyroid disorder market by 2035?**
A: The projected market valuation for 2035 is $186.6 Million.

**Q: What is the expected CAGR for the thyroid disorder market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 3.67%.

**Q: Which companies are considered key players in the thyroid disorder market?**
A: Key players include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Sanofi, Takeda Pharmaceutical Company, and AstraZeneca.

**Q: What are the market segments for thyroid disorders based on type?**
A: The market segments based on type include Hypothyroidism, valued between $80.0 Million and $120.0 Million, and Hyperthyroidism, valued between $45.56 Million and $66.6 Million.

**Q: What treatment options are available in the thyroid disorder market?**
A: Treatment options include Medications, valued between $75.0 Million and $110.0 Million, Surgery, valued between $30.0 Million and $45.0 Million, and Radioactive iodine therapy, valued between $20.56 Million and $31.6 Million.

**Q: What routes of administration are utilized in the thyroid disorder market?**
A: The routes of administration include Intravenous, valued between $15.0 Million and $22.0 Million, Oral, valued between $85.0 Million and $130.0 Million, and Other, valued between $25.56 Million and $34.6 Million.

**Q: What are the end-user segments in the thyroid disorder market?**
A: End-user segments include Clinics, valued between $30.0 Million and $45.0 Million, Hospitals, valued between $70.0 Million and $100.0 Million, and Others, valued between $25.56 Million and $41.6 Million.

**Q: How does the thyroid disorder market in India compare to global trends?**
A: While specific global comparisons are not provided, the growth trajectory in India, with a projected CAGR of 3.67%, suggests a robust market potential.

**Q: What factors may influence the growth of the thyroid disorder market in India?**
A: Factors influencing growth may include increasing awareness of thyroid disorders, advancements in treatment options, and the expanding healthcare infrastructure.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-thyroid-disorder-market-57009*